They're probably all correct. Just in different circumstances. The American Academy of Pediatrics Committee on Environmental Health recommendations for lead toxicity treatment are as follows:
BLL less than 10 μg/dL
No action is required
BLL 10-14 μg/dL
Obtain a confirmatory venous lead level within 1 month. If the BLL is still within this range, patient education about lead exposure is needed, and the BLL test should be repeated in 3 months.
BLL 15-19 μg/dL
Obtain a confirmatory venous lead level within 1 month. If the BLL is still within this range, patient education about lead exposure is needed, and the BLL test should be repeated in 2 months.
BLL 20-44 μg/dL
Obtain a confirmatory venous BLL in 1 week, and if the BLL is still within this range, assess complete medical, nutritional, and environmental hazards. Environmental evaluation by the local health department is also needed.
A large-scale study reported no improvement in neurologic and behavioral test scores after succimer chelation of children with BLL in this range.
BLL 45-69 μg/dL
Obtain a confirmatory BLL within 2 days, and if the level is still within this range, the patient should undergo the same complete evaluation as would patients with a BLL of 20-44 μg/dL. At 45-69 μg/dL, chelation therapy is recommended. Treatment should be in a lead-free environment. If this is not possible, hospitalization is necessary.
Chelation can be started with oral succimer, or, if the patient is hospitalized, calcium disodium edetate (calcium EDTA) can be used. These agents have potential toxicities, and monitoring of the CBC count, electrolytes, and liver function test results is necessary.
BLL 70 μg/dL or higher
Hospitalize the patient, obtain a confirmatory venous BLL, and initiate chelation with dimercaprol and calcium EDTA. Because calcium EDTA does not cross the blood-brain barrier, its use as the only agent in this situation is not recommended because of the possibility of lead redistribution from the soft tissues to the central nervous system (CNS). Pretreatment with dimercaprol (which crosses the blood-brain barrier) is recommended.